37 results about "Cancer Cause" patented technology

A fused ring compound, a pharmaceutical composition comprising same, and the use thereof. The compound has a structure as represented by formula (I), or is a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture form thereof, a metabolite, a metabolic precursor, an isotope-substituted form, a pharmaceutically acceptable salt, a hydrate, a solvate, a polymorph or a co-crystal thereof. The compound can be used for treating one or more cancers caused by KRAS mutation.

A fused ring compound, a pharmaceutical composition comprising same, and a use. The compound has a structure represented by formula (I) or a tautomer, mesomere, racemate, enantiomer, diastereomer or mixture thereof, metabolite, metabolic precursor, isotope substitution form, pharmaceutically acceptable salt, hydrate, solvate, polymorph or eutectic thereof. The compound can be used for treating a cancer caused by KRAS mutations, and said cancer is selected from one or more cancers caused by KRAS G12C, KRAS G12V, KRAS G12A and G12D mutations. In particular, the compound can serve as a G12D inhibitor and has relatively high inhibitory activity.

The invention discloses a fused ring compound, a pharmaceutical composition containing the fused ring compound and application. The compound has a structure as shown in a formula (I) or a tautomer, a meso-mer, a raceme, an enantiomer, a diastereoisomer or a mixture form, a metabolite, a metabolism precursor, an isotope substitution form, a pharmaceutically acceptable salt, a hydrate, a solvate, a polymorphic substance or an eutectic substance thereof, the compound can be used for treating one or more cancers caused by KRAS mutation.

The present invention describes an approach for improving immunogenic and therapeutic performance in the prevention and / or treatment of lesions and / or cancer caused by or associated with the human papillomavirus (HPV). More specifically, the approach involves a hybrid protein selected from two entities with improved immunogenic and therapeutic potential, use thereof and a formulation comprising same. Also disclosed are nucleotide sequences, a vector for the expression of recombinant proteins, as well as a process for producing a formulation comprising said entity and a therapeutic method. The invention applies to the fields of medicine, pharmacy and biotechnology.

The invention discloses a fused ring compound, a pharmaceutical composition containing the fused ring compound and application. The compound has a structure as shown in a formula (I) or a tautomer, a meso-mer, a raceme, an enantiomer, a diastereoisomer or a mixture form, a metabolite, a metabolism precursor, an isotope substitution form, a pharmaceutically acceptable salt, a hydrate, a solvate, a polymorphic substance or an eutectic substance thereof. The compound can be used for treating cancers caused by KRAS mutation, the cancers caused by KRAS mutation are selected from one or more of cancers caused by KRASG12C, KRASG12V, KRASG12A and G12D mutation, and particularly, the compound can be used as a G12D inhibitor and has relatively high inhibitory activity.

This invention discloses an enhanced TCR and its uses. The enhanced TCR includes an α-chain variable region containing CDR1α, CDR2α, and CDR3α, and a β-chain variable region containing CDR1β, CDR2β, and CDR3β; wherein the enhanced TCR has a T30H mutation relative to the parental TCR's CDR1α, or the enhanced TCR has an S102H or G99H mutation relative to the parental TCR's CDR3α. The enhanced TCR provided by this invention is obtained by mutation based on the parental TCR, possessing a highly sensitive ability to bind target antigen peptides, significantly improving target cell recognition ability, and mediating the specific killing effect of effector cells on antigen-positive target cells, and exhibiting no allogeneic reaction to different HLA subtypes. It can be used to treat various cancers caused by KRAS G12D positivity.

The invention discloses a preparation method of a nano-enzyme preparation as well as a product and application of the nano-enzyme preparation. The synthesis method of the nano-enzyme preparation comprises the following steps: mixing a transmembrane protein solution and a solution containing one or more nano-enzymes to prepare the nano-enzyme preparation. The nano-enzyme can target a disease site, and on one hand, the nano-enzyme removes active oxygen and active nitrogen species on the disease site; on the other hand, the nano-enzyme can be combined with cytokines of disease parts, the promotion effect of the cytokines on diseases is inhibited, and the effect of preventing and treating colitis and colitis-related colon cancer diseases is achieved. The nano-enzyme developed by the invention not only can relieve oxidative stress of diseases, but also can reduce the pro-inflammatory and tumor-promoting effects of cytokines, and can effectively treat colitis-related colon cancer caused by deterioration of colitis.

The invention discloses application of a Caspase-1 inhibitor in preparation of a medicine for preventing non-small cell lung cancer brain metastasis caused by drug resistance, and belongs to the technical field of biomedicine. The invention provides an application of a Caspase-1 inhibitor in preparation of a medicine for preventing brain metastasis of cancer caused by drug resistance. The invention also provides a pharmaceutical composition for preventing brain metastasis of cancer caused by drug resistance. The pharmaceutical composition comprises the Caspase-1 inhibitor. The Caspase-1 inhibitor can prevent or reduce the occurrence of drug-resistant brain metastasis in the non-small cell lung cancer treatment process, and provides a new strategy and drug for improving the prognosis of patients.

This invention provides a COX2 inhibitory peptide, a composition for inhibiting COX2, and its application, belonging to the field of bioactive peptide technology. The amino acid sequence of the COX2 inhibitory peptide of this invention includes RGPF, FPK, or NPW. Studies have found that COX2 inhibitory peptides with amino acid sequences such as RGPF, FPK, or NPW exhibit an IC50 (increase in activity) for inhibiting COX2 activity. 50 The values ​​were 360.17±32.60 μM, 640.33±10.29 μM, and 1100.90±89.93 μM, respectively, which can effectively inhibit the activity of COX2, thereby effectively preventing and / or treating inflammation and cancer caused by COX2, and also achieving antipyretic and analgesic effects. Meanwhile, the COX2 inhibitory peptide of this invention has the advantages of being safe, non-toxic, and highly water-soluble, providing a safe option for the clinical use of COX2 inhibitors.

The invention provides a COX2 inhibitory peptide, a composition for inhibiting COX2 and application, and belongs to the technical field of bioactive peptides. The amino acid sequence of the COX2 inhibitory peptide comprises RGPF, FPK or NPW. Research finds that IC50 values of COX2 activity inhibition of the COX2 inhibitory peptide with the amino acid sequence shown as RGPF, FPK or NPW are 360.17 + / -32.60 [mu] M, 640.33 + / -10.29 [mu] M and 1100.90 + / -89.93 [mu] M respectively, and the COX2 inhibitory peptide can effectively inhibit the activity of COX2, so that inflammation and cancers caused by COX2 are effectively prevented and / or treated, and the purposes of antipyretic and analgesic can be achieved. Meanwhile, the COX2 inhibitory peptide disclosed by the invention has the advantages of safety, no toxicity, good water solubility and the like, and provides a choice for safely using a COX2 inhibitor clinically.

The present invention relates to an antibody that specifically binds to mesothelin and use thereof. In an aspect of the present invention, it was confirmed that an anti-MSLN antibody or antigen-binding fragment thereof comprising a CDR consisting of a specific amino acid sequence binds to MSLN, which is an antigen, with very high specificity, and the anti-MSLN antibody or an antigen-binding fragment thereof can be used not only as a therapeutic agent capable of delivering a drug through cell internalization, but also as an anti-MSLN antibody-drug conjugate capable of killing cancer cells by targeting MSLN. Therefore, the anti-MSLN antibody or an antigen-binding fragment thereof, according to an aspect of the present invention, and a composition comprising same have an excellent effect of preventing or treating cancer caused by MSLN overexpression or predicting or diagnosing the cancer.

The present invention relates to the technical field of medicines, and provides a fused ring compound, a pharmaceutical composition containing the same, and use of the fused ring compound. The compound has a structure as shown in formula (I), or a tautomer, a mesomer, a racemat, an enantiomer, a diastereoisomer or a mixture thereof, a metabolite, a metabolic precursor, an isotope substitution form, a pharmaceutically acceptable salt, a hydrate, a solvate, a polymorph or a eutectic substance thereof. The compound provided by the present invention can be used for treating cancers caused by KRAS mutation. The cancers caused by KRAS mutation are selected from one or more cancers caused by KRAS G12C, KRAS G12V, KRAS G12A and G12D mutations. In particular, the compound can serve as a G12D inhibitor and has relatively high inhibitory activity.

The present invention belongs to the field of pharmaceutical chemistry, and specifically relates to a class of compounds shown in formula I or formula II as protein phosphatase 5 agonists, preparation methods thereof, and pharmaceutical compositions containing these compounds and applications of these compounds or compositions in drug preparation. The present invention provides a class of 2-imine-2H-chromene-3-thioamide protein phosphatase (PP5) agonists and derivatives thereof, by discovering active small molecules with novel structures and good physicochemical properties, and the small molecules have shown good activity in various experiments, directly targeting PP5 to produce agonistic effects, and provide a new solution for the treatment of related diseases caused by PP5 abnormalities, and is expected to be developed into specific drugs for the treatment of Alzheimer's disease, obesity caused by glucocorticoid treatment, and cancer caused by protease dephosphorylation dysfunction, and has clinical application value.

This invention belongs to the field of probiotic screening and application technology, specifically relating to a strain of *Lactobacillus paracasei* and its application in the prevention and treatment of colonic polyps and colon cancer. The *Lactobacillus paracasei*, named *Lactobacillus paracasei* V85, was deposited on January 15, 2026, at the China Center for Type Culture Collection (CCTCC), Wuhan University, China, with accession number CCTCC NO: M2026124. The *Lactobacillus paracasei* V85 provided by this invention is sensitive to common antibiotics and has good biosafety; it possesses strong antioxidant function and a strong inhibitory effect on hemolytic streptococci; it can produce a strong agglutination effect with hemolytic streptococci, which is beneficial for inhibiting the colonization of hemolytic streptococci in the intestine, reducing the risk of colonic polyps and colon cancer caused by hemolytic streptococci, and can promote the proliferation of *Akkermansia myxophilus*. It can be used to prevent and treat colonic polyps and colon cancer caused by hemolytic streptococci, and has broad application prospects.

The present invention provides compositions and methods for treating or ameliorating advanced cancers, such as drug-resistant or metastatic cancers, or killing cancer stem cells expressing an alpha v beta 3 polypeptide on its cell surface by using a human antibody or a humanized antibody, and the human antibody or humanized antibody is capable of specifically binding to an [alpha] v [beta] 3 (avb3) polypeptide expressed on the cell surface of effector cells such as macrophages, neutrophils and dendritic cells, the Fc region of which has selective affinity for human Fc [gamma] RI (CD64) but does not have selective affinity for other Fc [gamma] R. By administering these antibodies to an individual in need thereof, these human antibodies or humanized antibodies can treat, ameliorate, or slow the progression of advanced cancers or drug resistant cancers or cancers caused, initiated, or maintained by advanced cancers or drug resistant cancer cells or cancer stem cells.

The invention relates to the field of medicine, in particular to application of a substance specifically binding to ICAM1 in combination with an RET inhibitor in preparation of a product for treating cancers caused by RET variation, and the cancers caused by RET gene variation are solid tumors resistant to small-molecule inhibitors. The substance which is specifically bound with the ICAM1 is selected from an antibody coupling medicine, and the antibody coupling medicine is selected from anti-ICAM1mAb-MC-VC-PAB-MMAE or anti-ICAM1mAb-MC-GGFG-Dxd, and the substance which is specifically bound with the ICAM1 is selected from a substance which is specifically bound with the ICAM1, a substance which is specifically bound with the ICAM1 and a substance which is specifically bound with the ICAM1. According to the invention, a generally highly expressed antigen epitope ICAM1 is found in a solid tumor with RET gene variation, and the precise targeting effect and the efficient inhibition capability of ICAM1-MMAE and ICAM1-DXd on tumor cells with RET mutation are evaluated on the in-vivo and in-vitro aspects; the ICAM1-ADCs and the obtained specific RET inhibitor BLU-667 are combined for use, and the combined synergistic capability of the ICAM1-ADCs and the obtained specific RET inhibitor BLU-667 is evaluated.

The application provides a rapid dehydration and transparency method of pathological sections, and belongs to the technical field of tissue sample preparation. The rapid dehydration and transparency method comprises the following steps: dehydrating an in-vitro tissue by using ethanol solutions with volume concentrations from low to high, and then transparently treating the dehydrated in-vitro tissue in a fatty alcohol polyoxyethylene ether, wherein the temperature of the dehydration treatment and the transparency treatment is 55-65 DEG C. The application sets the temperature of the dehydration treatment and the transparency treatment as 55-65 DEG C, which significantly shortens the time of the dehydration treatment and the transparency treatment. The application replaces xylene, which is used in the traditional preparation of pathological sections, with a fatty alcohol polyoxyethylene ether, which not only avoids the risk of cancer caused by long-term contact with xylene, but also achieves the same transparency effect as xylene. Experimental results show that, compared with the traditional method, the pathological sections prepared by the application not only significantly shorten the time of dehydration and transparency treatment, but also do not affect the section quality due to the shortened time.

The present invention relates to an isoindolinone derivative compound having a quinoline-substituted glutarimide parent nucleus and an application thereof, and more particularly, to an isoindolinone derivative compound having a thalidomide analogue structure and having a quinoline-substituted glutarimide parent nucleus. The compound of chemical formula 1 according to the present invention specifically binds to CRBN protein and participates in its function. Therefore, the compound of the present invention can be effectively used for preventing or treating leprosy, chronic graft versus host disease, inflammatory disease or cancer caused by the action of CRBN protein.

The invention relates to a cRGD peptide modified targeting polymer vesicle as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a targeting polymer vesicle modified by cRGD peptide. The targeting polymer vesicle modified by the cRGD peptide is prepared from the following components: a targeting polymer cRGD-PEG-P (TMC-co-DTC), a carrier polymer PEG-P (TMC-co-DTC)-PEI1200 and a siKRAS medicine. The cRGD peptide modified targeted polymer vesicles can efficiently load siKRAS drugs, effective release of the siKRAS drugs in cells is achieved, enrichment and internalization of the vesicles in tumor sites in vivo are effectively improved, tumor growth of a KRAS G12D mutation pancreatic cancer model is well inhibited, the lifetime of model mice is remarkably prolonged, and the cRGD peptide modified targeted polymer vesicles are free of remarkable toxicity and can be applied to preparation of drugs for treating pancreatic cancer. The compound has a great application prospect in preparation of targeted therapeutic drugs for cancers caused by KRAS mutation.

The present invention belongs to the field of medical technology, and specifically relates to the use of a Chinese medicine compound composition in the preparation of a drug for resisting ulcerative colitis and intestinal fibrosis and colon cancer caused by colitis. The Chinese medicine compound composition of the present invention has significant effects on resisting acute ulcerative colitis, improving the degree of intestinal fibrosis caused by colitis, and resisting colon cancer, and can be used to improve and treat ulcerative colitis and intestinal fibrosis and colon cancer caused by colitis. The Chinese medicine compound composition resists acute ulcerative colitis by reducing the level of oxidative stress, inhibiting intestinal inflammation, restoring intestinal barrier function, and regulating immunity, and improves colon fibrosis and colon cancer caused by colitis. A new drug with significant efficacy and few adverse reactions is provided for patients with ulcerative colitis and intestinal fibrosis and colon cancer caused by colitis to relieve the suffering of patients.

The present invention provides a new flavonoid compound and its preparation method and application, belonging to the field of medical technology. The flavonoid compound is isolated from the Calophyllum membranaceum Gardn.et Champ. of the Guttiferae family. The dried stems and leaves of Calophyllum membranaceum are taken, and a new flavonoid compound is obtained by extract extraction, MCI segmentation decolorization, silica gel column chromatography, open ODS column chromatography, Sephadex LH-20 gel column chromatography, and semi-preparative HPLC chromatography: the preparation method of the present invention is simple to operate and has a high degree of purification. The flavonoid compound of the present invention can target and inhibit CYP1A1 enzyme activity, can be used as a lead compound for developing drugs that inhibit CYP1A1 enzyme activity, is expected to prevent or treat cancers caused by pro-carcinogens / mutagens such as polycyclic aromatic hydrocarbons and heterocyclic aromatic amines, and has potential clinical application value in the development of drugs such as anti-lung cancer, anti-breast cancer, and anti-colon cancer.

The present invention relates to an OMV vaccine that can prevent Helicobacter pylori infection and a preparation method thereof. The vaccine uses a conserved trisaccharide (Trio) in Helicobacter pylori lipopolysaccharide as a core antigen epitope, and its structure is α-DD-Hep-(1→3)-α-D-Fuc-(1→3)-β-D-GlcNAc-. The epitope is biosynthesized by recombinant Escherichia coli, and a non-reducing end of a core oligosaccharide on the Escherichia coli outer membrane vesicle (OMV) is used as a connection anchor. The oligosaccharide is catalyzed and synthesized by glycosyltransferases from Helicobacter pylori and Escherichia coli. Trio can be efficiently displayed on the surface of OMV using this oligosaccharide on the surface of bacteria. Animal experiments have shown that the vaccine has the ability to activate the body's immune response and protective efficacy, and can be developed as a vaccine to prevent Helicobacter pylori infection. It has important application value and significance for effectively preventing and treating diseases such as peptic ulcers, chronic inflammation, and even gastric cancer caused by Helicobacter pylori infection.

The present invention relates to an isoindolinone derivative compound having a glutarimide parent nucleus and an application thereof, and more particularly, to an isoindolinone derivative compound having a phenyl cyclopropane substituted glutarimide parent nucleus and having a thalidomide analogue structure. The compound of chemical formula 1 according to the present invention specifically binds to CRBN protein and participates in its function. Therefore, the compound of the present invention can be effectively used for preventing or treating leprosy, chronic graft versus host disease, inflammatory disease or cancer caused by the action of CRBN protein.

The object of the present disclosure is to provide a protein that selectively recognizes cancer caused by a mutation of K-Ras gene (herein particularly referred to as "K-Ras gene mutation cancer"). Provided are a production method of a protein that selectively recognizes K-ras gene mutation cancer characterized in that it comprises first to third steps of linking first to third specific sugar chains respectively to lysine residues on the protein molecule, as well as the protein produced by the aforementioned method. Moreover, a pharmaceutical composition for cancer therapy comprising said protein is provided.

The present invention provides: a novel pyrimidine derivative compound that inhibits the growth of cancer cells; and a pharmaceutical composition for preventing and treating cancers including lung cancer, the composition containing a pharmaceutically acceptable salt of the compound as an active ingredient. In particular, the novel compound according to the present invention has an excellent inhibitory effect on exon 20 insertion EGFR mutants and excellent selectivity to wild-type EGFR, and is useful as an agent for preventing, alleviating and treating cancers caused by these EGFR mutant species.

This invention belongs to the field of functional probiotic screening and application technology, specifically involving a novel strain of *Lactobacillus plantarum* (…). Lactiplantibacillus plantarum The *Lactobacillus plantarum* strain was deposited on January 15, 2026, at the China Center for Type Culture Collection (CCTCC), Wuhan University, Wuhan, China, with accession number CCTCC NO: M202026133. This strain exhibits strong antioxidant capacity, significant inhibitory and flocculating effects against hemolytic streptococci, and can significantly reduce the levels of pro-inflammatory cytokines IL-6 and IL-1β induced by hemolytic streptococci while increasing the level of the anti-inflammatory cytokine IL-22. It has no toxic effects on the body, good safety profile, and can be used to prevent colonic polyps and colon cancer caused by hemolytic streptococci, showing broad application prospects.

The invention relates to traditional Chinese medicine external gel for preventing or treating HPV (human papillomavirus) infection as well as a preparation method and application of the traditional Chinese medicine external gel. The traditional Chinese medicine external gel comprises an active composition and a gel matrix, the active composition comprises a traditional Chinese medicine extract and menthol, and the traditional Chinese medicine extract comprises the following raw materials in parts by weight: 9-15 parts of radix sophorae flavescentis, 9-15 parts of cortex phellodendri, 12-20 parts of rhizoma smilacis glabrae, 9-12 parts of honeysuckle, 9-12 parts of fructus forsythiae, 6-12 parts of safflower, 12-20 parts of fructus cnidii, 6-12 parts of rhizoma bletillae, 6-12 parts of radix aucklandiae and 12-20 parts of cockscomb; 5 to 10 parts by weight of menthol; the weight part of the gel matrix is 260 to 800 parts. The traditional Chinese medicine external gel provided by the invention can effectively inhibit HPV virus replication, treat cervical precancerous lesions caused by HPV infection and prevent cancers caused by HPV infection, and the traditional Chinese medicine external gel is convenient to use, stable in action effect and high in safety, and has important clinical significance.

The invention provides an application of an STT3A gene inhibitor in treatment of RSPO and / or RNF43 / ZNRF3 gene mutation type cancers. The STT3A gene inhibitor can be used for treating the RSPO and / or RNF43 / ZNRF3 gene mutation type cancers. Specifically, the STT3A gene inhibitor can inhibit N-glycosylation modification of LRP6, so that abnormal activation of a Wnt pathway caused by RSPO and / or RNF43 / ZNRF3 gene mutation is inhibited, and cancers caused by abnormal activation of the Wnt pathway are treated. In addition, the invention also provides a pharmaceutical composition and a treatment method for treating RSPO and / or RNF43 / ZNRF3 gene mutant cancers.

This invention relates to the pyrazolo[1,5-a]pyrimidine derivative of Formula I, its preparation method, and its uses. It can be used as a PI3Kα inhibitor to treat cancers caused by dysregulation of the PI3Kα signaling pathway, such as breast cancer, lung cancer, or rectal cancer. Furthermore, the preparation method of this compound is simple and it has certain application prospects.

This invention belongs to the field of probiotic screening and application technology, specifically relating to a strain of *Lactobacillus rhamnosus* and its application in the prevention and treatment of colon polyps and colon cancer. The *Lactobacillus rhamnosus* is named *Lactobacillus rhamnosus* (…). Lacticaseibacillus rhamnosus S28, deposited on January 15, 2026, at the China Center for Type Culture Collection (CCTCC), Wuhan University, Wuhan, China, with accession number CCTCC NO: M2026129, exhibits strong inhibitory activity against *Streptococcus bovis* and demonstrates a strong agglutination effect with it. It can be used to prevent or treat colonic polyps and colon cancer caused by *Streptococcus bovis*. This invention also provides probiotic pellets containing *Lactobacillus rhamnosus* S28, which exhibit strong resistance, effectively protecting the probiotics from gastric digestion, ensuring their smooth arrival in the intestines, and achieving rapid disintegration within the intestines, showing broad market prospects.